Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 24;95(1):42-48.
doi: 10.24875/ACM.24000020.

Decompensated heart failure in a single center of a Latin American country: findings from the first 1595 cases in the ICARUS registry

Affiliations

Decompensated heart failure in a single center of a Latin American country: findings from the first 1595 cases in the ICARUS registry

Lyda Z Rojas et al. Arch Cardiol Mex. .

Abstract

Objective: Describe the methodological aspects, sociodemographic, and clinical characteristics of patients hospitalized with acute decompensated heart failure (ADHF) and their short-term outcomes.

Methods: Prospective cohort of patients with ADHF from the emergency service of the cardiovascular center. Descriptive statistics were used to synthesize sociodemographic characteristics, clinical characteristics during hospitalization, and outcomes.

Results: 1595 patients with ADHF. The median age was 68 years (Q1 = 58; Q3 = 76), and 69.28% were men. The median hospital stay was 6 days (Q1 = 4; Q3 = 11), with an cumulative incidence for re-hospitalization at 30 days of 8.70% (95% CI 7.18-10.40%), in-hospital mortality cumulative incidence of 4.33% (95% CI 3.38-5.44%), and a median change in the quality-of-life score Minnesota Living with Heart Failure at 30 days of -20 points (Q1 = -37; Q3 = -5). At discharge, all patients had a percentage > 70% of the use of quadruple neurohormonal blockade therapy.

Conclusion: Institutional aCute decompensAted HeaRt FailUre RegiStry (ICARUS) is one of the first studies in Latin America to demonstrate the importance of characterizing the population with ADHF and the adherence to heart failure guidelines may have influenced the favorable clinical outcomes.

Objetivo: Describir los aspectos metodológicos, las características sociodemográficas y clínicas de los pacientes hospitalizados con ICAD y sus desenlaces a corto plazo.

Método: Cohorte prospectiva de pacientes con ICAD del servicio de urgencias de un centro Cardiovascular, en el que se evaluaron datos provenientes de seguimiento telefónico y plataforma REDCap. Se utilizó estadística descriptiva para sintetizar las características sociodemográficas y clínicas durante la hospitalización y los resultados.

Resultados: 1595 pacientes con ICAD. La mediana de edad fue de 68 años (Q1 = 58; Q3 = 76), y el 69,28% eran hombres. La mediana de estancia hospitalaria fue de 6 días (Q1 = 4; Q3 = 11), con una IA de re-hospitalización a los 30 días de 8.70% (IC 95% 7.18 a 10.40%), incidencia acumulada de mortalidad hospitalaria de 4.33% (IC 95% 3.38 a 5.44%) y una mediana de cambio en el puntaje de calidad de vida (MLHFQ) a los 30 días de −20 puntos (Q1 = −37; Q3 = −5). Al alta, todos los pacientes tenían un porcentaje mayor del 70% de uso de cuádruple terapia de bloqueo neurohormonal.

Conclusiones: Institutional aCute decompensAted HeaRt FailUre RegiStry (ICARUS) es uno de los primeros estudios en América Latina en evidenciar la importancia de la caracterización de la población con ICAD, y la adherencia a las guías de insuficiencia cardíaca podría haber influido en los resultados clínicos favorables.

Keywords: Heart decompensation; Heart failure; Hospitalization; Latin America; Mortality.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Proportion of heart failure drug group at hospital admission and discharge in Institutional aCute decompensAted HeaRt FailUre RegiStry (n = 1595). ACEI: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; ARNIs: angiotensin receptor-neprilysin inhibitors; MRAs: aldosterone receptor antagonists; SGLT2i: sodium-glucose cotransporter-2 inhibitors.
Figure 2
Figure 2
Outcomes in Institutional aCute decompensAted HeaRt FailUre RegiStry.

References

    1. Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K, et al. Acute heart failure. Nat Rev Dis Primers. 2020;6:16. - PMC - PubMed
    1. Cavalcante JL, Khan S, Gheorghiade M. EVEREST study:efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan. Expert Rev Cardiovasc Ther. 2008;6:1331–8. - PubMed
    1. Ciapponi A, Alcaraz A, Calderon M, Matta MG, Chaparro M, Soto N, et al. Burden of heart failure in Latin America:a systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed) 2016;69:1051–60. - PubMed
    1. Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure:a systematic review 2004-2016. BMC Cardiovasc Disord. 2018;18:74. - PMC - PubMed
    1. Voigt J, Sasha John M, Taylor A, Krucoff M, Reynolds MR, Michael Gibson C. A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. Clin Cardiol. 2014;37:312–21. - PMC - PubMed

LinkOut - more resources